Sugi Predict

Sugi Predict / Compounds / SCHEMBL517067

SCHEMBL517067

SCHEMBL517067

O=C1Cc2cc(S(=O)(=O)Cl)ccc2N1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 10/20 0.60
▸ AHR P35869 1/20 0.59
▸ PKM P14618 2/20 0.53
▸ SMYD3 Q9H7B4 1/20 0.53
▸ IDO1 P14902 1/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ PGR P06401 1/20 0.49
▸ PDE3B Q13370 1/20 0.49
▸ PDE3A Q14432 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586707 0.85 PKM (0.60) PKMIDO1
SCHEMBL30114411 0.85 PKM (0.60) PKMIDO1
SCHEMBL689168 0.83 GAA (0.60) GAAAHRPKMSMYD3IDO1
SCHEMBL10293161 0.83 GAA (0.60) GAAAHRPKMSMYD3IDO1
SCHEMBL1556955 0.83 GAA (0.60) GAAAHRPKMSMYD3IDO1
SCHEMBL2203244 0.83 GAA (0.64) GAAAHRPKMSMYD3IDO1
SCHEMBL22400700 0.82 PKM (0.56) PKMIDO1MAPT
SCHEMBL17231399 0.81 GAA (0.41) GAAAHRPKMSMYD3IDO1
Hydrochloric Acid SCHEMBL28865546 0.81 GAA (0.62) GAAAHRPKMSMYD3IDO1
SCHEMBL6602558 0.80 GAA (0.57) GAAAHRPKMSMYD3IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669088-B N- (2-ethylamine) benzenesulfonylamino cordycepin derivative and preparation method and application thereof 成都阿奇生物医药科技有限公司 2023-03-28 — — CN claimed
WO-2021260722-A1 DESIGN, SYNTHESIS OF NOVEL OXYINDOLE INHIBITORS OF DENV RNA DEPENDENT RNA POLYMERASE TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) 2021-12-30 — — WO claimed
CN-110669088-A N- (2-ethylamine) benzenesulfonylamino cordycepin derivative and preparation method and application thereof 成都阿奇生物医药科技有限公司 2020-01-10 — — CN claimed
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 — — US disclosed
US-12428394-B2 2,4-disubstituted pyrimidine derivative, preparation method therefor and use thereof CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2025-09-30 — — US disclosed
CN-118955475-A Compound for inhibiting tumor cells and application thereof 中国人民解放军军事科学院军事医学研究院 2024-11-15 — — CN disclosed
EP-3985000-B1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) 2024-09-25 — — EP disclosed
WO-2024120519-A1 TEAD INHIBITOR, PREPARATION METHOD THEREFOR. AND MEDICAL USE THEREOF 捷思英达控股有限公司 2024-06-13 — — WO disclosed
CN-114423750-B 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof 成都赜灵生物医药科技有限公司 2024-04-19 — — CN disclosed
CN-114181199-B 2, 4-disubstituted pyrimidine derivative, preparation method and application thereof 成都赜灵生物医药科技有限公司 2023-09-26 — — CN disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 — — US disclosed
US-6051593-A USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-04-18 — — US disclosed
EP-0984930-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY Sugen, Inc. (US) 2000-03-15 — — EP disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 — — WO disclosed
WO-1999061422-A1 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 1999-12-02 — — WO disclosed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 — — WO disclosed
EP-0912557-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1999-05-06 — — EP disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 — — WO disclosed
WO-1998007742-A1 SULFONAMIDES ZENECA LIMITED (GB) 1998-02-26 — — WO disclosed
WO-1997042187-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1997-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF GAA 996/4885AHR 347/4885PKM 3496/4885
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 GAA 1736/4885AHR 258/4885PKM 4352/4885
US-12428394-B2 2,4-disubstituted pyrimidine derivative, preparation method therefor and use thereof JAK2, FLT3, JAK1 GAA 3635/4885AHR 957/4885PKM 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.